loading
Sagimet Biosciences Inc stock is traded at $8.25, with a volume of 826.73K. It is down -5.06% in the last 24 hours and up +2.74% over the past month. Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.
See More
Previous Close:
$8.69
Open:
$8.6
24h Volume:
826.73K
Relative Volume:
0.56
Market Cap:
$253.07M
Revenue:
-
Net Income/Loss:
$-29.25M
P/E Ratio:
-6.9562
EPS:
-1.186
Net Cash Flow:
$-22.80M
1W Performance:
-19.43%
1M Performance:
+2.74%
6M Performance:
+87.50%
1Y Performance:
+137.07%
1-Day Range:
Value
$7.98
$8.81
1-Week Range:
Value
$7.98
$10.46
52-Week Range:
Value
$1.73
$11.41

Sagimet Biosciences Inc Stock (SGMT) Company Profile

Name
Name
Sagimet Biosciences Inc
Name
Phone
(650) 561-8600
Name
Address
155 BOVET RD., SUITE 303, SAN MATEO
Name
Employee
14
Name
Twitter
Name
Next Earnings Date
Name
Latest SEC Filings
Name
SGMT's Discussions on Twitter

Compare SGMT with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
SGMT
Sagimet Biosciences Inc
8.25 279.78M 0 -29.25M -22.80M -1.186
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
462.13 117.32B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
558.87 58.89B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
401.80 51.14B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
673.80 41.02B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
299.01 32.59B 3.81B -644.79M -669.77M -6.24

Sagimet Biosciences Inc Stock (SGMT) Upgrades & Downgrades

Date Action Analyst Rating Change
Jul-24-25 Initiated Canaccord Genuity Buy
Dec-06-24 Initiated Oppenheimer Outperform
Nov-12-24 Initiated UBS Buy
Jun-28-24 Downgrade Goldman Buy → Neutral
May-02-24 Initiated H.C. Wainwright Buy
Mar-25-24 Initiated Leerink Partners Outperform
Aug-08-23 Initiated Goldman Buy
Aug-08-23 Initiated JMP Securities Mkt Outperform
Aug-08-23 Initiated Piper Sandler Overweight
Aug-08-23 Initiated TD Cowen Outperform
View All

Sagimet Biosciences Inc Stock (SGMT) Latest News

pulisher
12:22 PM

What are the technical indicators suggesting about Sagimet Biosciences Inc.Free Stock Outlook That Work - jammulinksnews.com

12:22 PM
pulisher
Aug 01, 2025

Wyckoff Accumulation Phase Possible in Sagimet Biosciences Inc.Entry Alert Based on Volume Spikes Detected - metal.it

Aug 01, 2025
pulisher
Jul 31, 2025

What makes Sagimet Biosciences Inc. stock price move sharplyMarket Forecast Alerts Backed By Experts - jammulinksnews.com

Jul 31, 2025
pulisher
Jul 31, 2025

What are the latest earnings results for Sagimet Biosciences Inc.Swing Trade Updates To Watch Now - jammulinksnews.com

Jul 31, 2025
pulisher
Jul 30, 2025

Can Sagimet Biosciences Inc. hit a new high this monthTrade Setups With Clear Risk Limits Highlighted - metal.it

Jul 30, 2025
pulisher
Jul 30, 2025

Why Sagimet Biosciences Inc. stock attracts strong analyst attentionEntry Alert With Low Drawdown Strategy Noted - beatles.ru

Jul 30, 2025
pulisher
Jul 30, 2025

Sagimet Biosciences Inc. Stock Performance After Earnings: Historical InsightsWeekly Portfolio Update with ROI Focus - Newser

Jul 30, 2025
pulisher
Jul 30, 2025

Risk adjusted return profile for Sagimet Biosciences Inc. analyzedFree Alert Feed for Momentum Based Picks - Newser

Jul 30, 2025
pulisher
Jul 30, 2025

How high can Sagimet Biosciences Inc. stock price go in 2025Daily Stock Forecast Powered by AI Tools - Newser

Jul 30, 2025
pulisher
Jul 29, 2025

How Sagimet Biosciences Inc. stock performs during market volatilityCommunity Strategy With High Win Rate Backtested - metal.it

Jul 29, 2025
pulisher
Jul 29, 2025

Custom watchlist performance reports with Sagimet Biosciences Inc.Secure Asset Flow and Trend Pattern Analysis - Newser

Jul 29, 2025
pulisher
Jul 29, 2025

Sagimet Biosciences Inc. Enters Reversal Setup in Weekly ChartsLow Volatility Stable Growth Picks Rank High - metal.it

Jul 29, 2025
pulisher
Jul 29, 2025

Is Sagimet Biosciences Inc. stock reversal real or fakeMulti-Year Signal Summary and Entry Timing - Newser

Jul 29, 2025
pulisher
Jul 29, 2025

Chart Patterns Forming a Bullish Setup in Sagimet Biosciences Inc.Investment Plan With Growth Optimization Finalized - metal.it

Jul 29, 2025
pulisher
Jul 29, 2025

Sagimet Biosciences Inc. (NASDAQ:SGMT) Receives $26.83 Consensus Target Price from Brokerages - Defense World

Jul 29, 2025
pulisher
Jul 29, 2025

Published on: 2025-07-29 07:13:29 - metal.it

Jul 29, 2025
pulisher
Jul 28, 2025

How Efficient Is Sagimet Biosciences Inc. at Controlling Operating CostsRisk Limited High Gain Trades - beatles.ru

Jul 28, 2025
pulisher
Jul 28, 2025

Sagimet Biosciences Inc. Company Revenue and Profit Trends: A Deep Dive Strategy Playbook for Risk Controlled Trades - Newser

Jul 28, 2025
pulisher
Jul 28, 2025

Sagimet Biosciences (NASDAQ:SGMT) Now Covered by Analysts at Canaccord Genuity Group - MarketBeat

Jul 28, 2025
pulisher
Jul 28, 2025

Reviewing Sagimet Biosciences (NASDAQ:SGMT) & Eledon Pharmaceuticals (NASDAQ:ELDN) - Defense World

Jul 28, 2025
pulisher
Jul 28, 2025

What are analysts’ price targets for Sagimet Biosciences Inc. in the next 12 monthsFinancial News Trend Scanner For Every Investor - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

Should I hold or sell Sagimet Biosciences Inc. stock in 2025Consistent triple-digit returns - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 27, 2025

How does Sagimet Biosciences Inc. compare to its industry peersMaximize portfolio value with smart investment plans - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

What catalysts could drive Sagimet Biosciences Inc. stock higher in 2025Gain insights from top financial experts - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

Sagimet Biosciences Inc. Company Revenue and Profit Trends: A Deep DiveSteady Profit Stock Forecasts - Newser

Jul 27, 2025
pulisher
Jul 27, 2025

Sagimet Biosciences (NASDAQ:SGMT) Earns Buy Rating from Analysts at Canaccord Genuity Group - Defense World

Jul 27, 2025
pulisher
Jul 26, 2025

Sagimet Biosciences Bets Big On First-In-Class Fatty Acid Blockers - Finimize

Jul 26, 2025
pulisher
Jul 25, 2025

What analysts say about Sagimet Biosciences Inc. stockPhenomenal wealth increase - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 24, 2025

Sagimet Biosciences Inc (SGMT) Stock: Navigating a Year of Volatility - investchronicle.com

Jul 24, 2025
pulisher
Jul 24, 2025

Strategic Catalysts and Valuation Upside in Sagimet Biosciences (SGMT): A M&A-Driven Biotech Play - AInvest

Jul 24, 2025
pulisher
Jul 24, 2025

Sagimet stock gains as Canaccord starts with Buy (SGMT:NASDAQ) - Seeking Alpha

Jul 24, 2025
pulisher
Jul 24, 2025

This Sarepta Therapeutics Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday - Benzinga

Jul 24, 2025
pulisher
Jul 24, 2025

Sagimet Biosciences Inc. Stock Analysis and ForecastBreakthrough capital growth - Autocar Professional

Jul 24, 2025
pulisher
Jul 23, 2025

Top Executives at Sagimet Biosciences Unload Significant Shares! - TipRanks

Jul 23, 2025
pulisher
Jul 23, 2025

What drives Sagimet Biosciences Inc. stock priceMarket-crushing stock picks - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

Sagimet Biosciences Executives Sell Shares to Cover Tax Obligations - TradingView

Jul 23, 2025

Sagimet Biosciences Inc Stock (SGMT) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Sagimet Biosciences Inc Stock (SGMT) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Martins Eduardo Bruno
Chief Medical Officer
Jul 21 '25
Sale
9.13
8,277
75,607
106,936
Rozek Elizabeth
General Counsel and CCO
Jul 21 '25
Sale
9.13
10,780
98,471
183,726
$75.59
price up icon 0.93%
$37.11
price up icon 0.84%
$108.69
price up icon 1.31%
$27.07
price up icon 2.65%
$107.34
price down icon 0.15%
biotechnology ONC
$299.01
price down icon 0.70%
Cap:     |  Volume (24h):